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Ellen A.W. Blokland,2 Tim M. Strom,10 Caroline C.W. Klaver,11,12 Raheel Qamar,6,13 Sandro Banfi,14
Frans P.M. Cremers,2,4 Dror Sharon,1,16,* and Anneke I. den Hollander2,3,4,16,*
Retinitis pigmentosa (RP) is a heterogeneous group of inherited retinal diseases caused by progressive degeneration of the photoreceptor
cells. Using autozygosity mapping, we identified two families, each with three affected siblings sharing large overlapping homozygous
regions that harbored the IMPG2 gene on chromosome 3. Sequence analysis of IMPG2 in the two index cases revealed homozygous
mutations cosegregating with the disease in the respective families: three affected siblings of Iraqi Jewish ancestry displayed a nonsense
mutation, and a Dutch family displayed a 1.8 kb genomic deletion that removes exon 9 and results in the absence of seven amino acids
in a conserved SEA domain of the IMPG2 protein. Transient transfection of COS-1 cells showed that a construct expressing the wild-type
SEA domain is properly targeted to the plasma membrane, whereas the mutant lacking the seven amino acids appears to be retained in
the endoplasmic reticulum. Mutation analysis in ten additional index cases that were of Dutch, Israeli, Italian, and Pakistani origin and
had homozygous regions encompassing IMPG2 revealed five additionalmutations; four nonsensemutations and onemissensemutation
affecting a highly conserved phenylalanine residue. Most patients with IMPG2 mutations showed an early-onset form of RP with
progressive visual-field loss and deterioration of visual acuity. The patient with the missense mutation, however, was diagnosed with
maculopathy. The IMPG2 gene encodes the interphotoreceptor matrix proteoglycan IMPG2, which is a constituent of the interphotor-
eceptor matrix. Our data therefore show that mutations in a structural component of the interphotoreceptor matrix can cause arRP.Introduction
Retinitis pigmentosa (RP) (MIM #268000), with a world-
wide prevalence of about 1:4,000,1–3 is a group of heredi-
tary retinal degenerative diseases and is considered one
of the most heterogeneous genetic diseases in humans.
The retinal phenotype in patients with RP is usually caused
by progressive degeneration of the rod photoreceptor cells
and the subsequent degeneration of cones. This results in
night blindness followed by gradual loss of visual fields
and visual acuity and often progresses to blindness by
the end of the sixth decade of life.4 The disease presents
with different modes of inheritance, including auto-
somal-recessive (50%–60% of cases), autosomal-dominant
(30%–40% of cases), and X-linked (5%–15% of cases).5 A
total of 27 genes have so far been found to cause nonsyn-
dromic autosomal-recessive RP (arRP), and four additional
loci have been identified by linkage studies (see the RetNet
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The Americonly by the large number of causative genes but also by
the variable mechanisms in which the encoded proteins
participate; such mechanisms include the phototransduc-
tion pathway, vitamin A metabolism, and the splicing
machinery.5 During the last two decades, two main
methods have been used for identifying arRP genes: the
candidate gene approach,6 in which genes are screened
for mutations mostly on the basis of the known or putative
function of the encoded protein, and homozygosity
mapping in large consanguineous families and subsequent
mutation analysis of genes in the linked interval. Using
these methods, researchers identified genes encoding
proteins that are localized mainly to the photoreceptors
and the retinal pigment epithelium (RPE). However, less
attention was drawn to the retinal extracellular matrix
(ECM), also known as the interphotoreceptor matrix
(IPM), which fills the space between individual photore-
ceptor cells and between photoreceptors and the RPE.
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glycoproteins, and proteoglycans7,8 and was considered
for many years to serve as a glue between the photorecep-
tors and the RPE cells.9 Data that has accumulated since
then has revealed a broader IPM function, including inter-
cellular communication, membrane turnover, regulation
of neovascularization, cell survival, photoreceptor differ-
entiation and maintenance, retinoid transport, and matrix
turnover.10,11 In addition, the IPM is thought to be impor-
tant for the precise alignment of the photoreceptor cells to
the optical light path.12 A link between an abnormal IPM
function and photoreceptor degeneration was obtained
by a study in which inhibition of proteoglycan synthesis
(by intravitreal injection of xyloside) caused both degener-
ation of the outer segment of cone photoreceptors and
retinal detachment.13 Only a few genes encoding proteins
that are known or speculated to be localized to the IPMhad
thus far been associated with a retinal disease. These
included TIMP3 (MIM *188826), causing Sorsby’s fundus
dystrophy14 (MIM #136900); EFEMP1 (MIM *601548),
causing dominant Doyne’s honeycomb retinal degenera-
tion15 (MIM #126600); IRBP (MIM *180290), causing
arRP;16 EYS (MIM *612424), causing arRP;17,18 and
ADAM9 (MIM *602713), causing autosomal-recessive
cone-rod degeneration (MIM #612775).19
In the current studywe performed autozygositymapping
to identify novel genes for arRP and Leber congenital
amaurosis (LCA), amore severe, congenital retinal disorder.
We identified six patients from two families, one Israeli and
one Dutch, who had homozygous regions with an overlap-
ping interval of 7.3 Mb on chromosome 3. This region
contains the retina-specific IMPG2 gene encoding the inter-
photoreceptor matrix proteoglycan 2. Sequence analysis
identified IMPG2mutations in both families. Further anal-
ysis of Israeli, Palestinian, and European RP families
revealed five additional mutations in IMPG2, underlining
the importance of the IPM in the pathogenesis of arRP.Subjects and Methods
Families and Genetic Analysis
The tenets of the Declaration of Helsinki were followed,
and informed consent was obtained from all participating
patients prior to donation of a blood sample. Blood
samples for DNA analysis were obtained from affected
and unaffected family members. Genomic DNA was
extracted from peripheral blood samples with the Flexi-
Gene DNA kit (QIAGEN, Germany) or by a standard
salting-out procedure.Clinical Evaluation
Complete ophthalmic examinations were performed in all
patients with mutations in IMPG2 and included both elec-
troretinography (ERG) according to ISCEV standards20 and
fundus photography. For some patients, additional clinical
tests consisting of visual-field measurements were
conducted with Goldmann kinetic perimetry or Optical200 The American Journal of Human Genetics 87, 199–208, August 1Coherence Tomography (OCT) performed with Heidelberg
Spectralis equipment.Homozygosity Mapping and Mutation Detection
Whole-genome SNP analysis was performed with the
Illumina 6K or Affymetrix 10K, 250K, 5.0, or 6.0 SNP
arrays. Homozygous regions were calculated with Partek
software, and parametric multipoint linkage analysis was
performed with Allegro in the EasyLinkage software
package. For fine mapping genomic regions of interest,
microsatellite markers were genotyped in affected and
unaffected family members. Primers for PCR amplification
of the 19 exons and exon-intron boundaries of IMPG2were
designed with Primer 3 software21 (Table S1). PCR was
performed on 50 ng of genomic DNA in 25 ml reactions
with 35 cycles. PCR fragments were purified with Exo
nuclease I and FastAP (Fermentas, Canada) or with
96-well PCR filter plates (Millipore), and mutation analysis
was performed by direct sequencing of PCR products.
To determine the boundaries of the genomic deletion
that was detected in family W01-299, we performed PCR
analysis by using combinations of several primers located
in introns 8 and 9 of the IMPG2 gene. Primer sequences
used in this analysis are available on request.DNA Constructs
The coding sequence of human IMPG2 (UniProt_ID
Q9BXV3) was amplified by PCR from human retina Mara-
thon-ready cDNA (Clontech, Mountain View, USA) with
forward primer 5-GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGCCGCC
ACCATGATTATGTTTCCTCTTTTTGG-30 and reverse primer 50-GGGGAC
CACTTTGTACAAGAAAGCTGGTCAACCTCTTCCACTTGTTGCTC-30 contain-
ingadapters forGatewaycloning (underlined). Entry clones
were generated by Gateway technology (Invitrogen, Leek,
The Netherlands) according to the manufacturer’s
instructions. A construct that contains the first SEA domain
of human IMPG2 (amino acids 239–349) was generated by
PCR using the full-length IMPG2 entry clone as a template
and using forward primer 50-GGGGACAAGTTTGTACAAAAAAG-
CAGGCTTCGGTGAACAGATTGCAGAATTC-30 and reverse primer 50-G
GGGACCACTTTGTACAAGAAAGCTGGTCTTAATAAACAACAGTGGGTTTATC-30.
From this construct, an entry clone containing a mutant
SEA domain (without the seven amino acids encoded by
exon 9, coined the DRSPKEND mutant) was generated via
site-directed mutagenesis with primers 50-CATAGTAAACATCTAC
GCCACTAAATTCAAGTACACG-30 and 50-CGTGTACTTGAATTTAGTGGCGTA-
GATGTTTACTATG-30. The sequence of all entry clones was
verified in sense and antisense directions with dye termina-
tion chemistry on a 3730 DNA analyzer (Applied Biosys-
tems Inc., Nieuwerkerk aan de Ijssel, The Netherlands).
Gateway technology was used for cloning the wild-type
SEA domain and the DRSPKEND mutant construct into
the pSeqTag expression vector that contains a cytomegalo
virus promoter, a signal peptide sequence for entering the
secretory pathway, the cDNA-encoding-enhanced cyan
fluorescent protein (eCFP), and then the sequence of3, 2010
Table 1. Families with Homozygous Regions Encompassing IMPG2
Family
Affected
Individuals
Level of
Consanguinity Origin
SNP
array
type Flanking SNPs
Size of
Homozygous
Region (Mb)
Mutation in
IMPG2 (Effect on
Protein)
MOL0764 3 First cousins Iraqi Jew Affy 10K rs1036051; rs326333 38.0 c.635C > G (p.Ser212X)
W01-299 3 None Dutch Affy 250K rs12330531; rs2290477 12.8 c.888-1554_908þ274 del
(p.Arg296_Asp302 del)
MOL0097 1 First cousins Palestinian Muslim Affy 10K rs1351109; rs722813 24.8 None
MOL0260 1 First cousins Israeli Muslim Affy 10K rs1523448; rs1259489 55.4 None
MOL0317 1 First cousins Israeli Muslim Affy 10K rs2325036; rs2134655 28.0 None
MOL0408 1 Second cousins Russian Jew Affy 10K rs831451; rs907931 58.5 None
W08-0023 1 First cousins Dutch Affy 5.0 rs4677400; rs358912 80.8 None
W08-1378 2 Second cousins Dutch Affy 6.0 rs17018482; rs103218337 22.0 c.2716C>T (p.Arg906X)
NAP1 1 Second cousins Italian Affy 5.0 rs9289536; rs7630522 13.6 c.2890C>T (p.Arg964X)
NAP75 1 First cousins Italian Affy 5.0 rs301930; rs7625411 15.4 c.3262C>T (p.Arg1088X)
RP49 3 First cousins Pakistan Illumina 6K rs1320173; rs1920325 42.3 c.1680T>A (p.Tyr560X)
MOL0732 1 First cousins Israeli Christian Arab Illumina 6K rs877523; rs1997422 59.2 c.370T>C (p.Phe124Leu)
Families with mutations in IMPG2 are indicated in italics. The pedigrees of families MOL0764 and W01-299 are shown in Figure 1.interest, thereby yielding pSeqTag- IMPG2 SEA wild-type
and pSeqTag-IMPG2 SEA DRSPKEND.Cell Culture, Transfections, and Fluorescence
Microscopy
COS-1 cells were cultured at 37C in DMEM (Sigma-Al-
drich, Zwijndrecht, The Netherlands) supplemented with
10% fetal calf serum (Sigma-Aldrich), 100 IU/ml penicillin,
100 mg/ml streptomycin, 10 mM sodium pyruvate (Sigma-
Aldrich), and 1% Glutamax (Sigma-Aldrich). Cells were
seeded on coverslips, and Effectene (QIAGEN, Venlo, The
Netherlands) was used for transfecting cells with pSeqTag
IMPG2 SEA wild-type or pSeqTag IMPG2 SEA DRSPKEND.
After 24 hr, cells were fixed in ice-cold methanol for
10 min, treated with 1% Triton X-100 in phosphate-buff-
ered saline (PBS) for 5 min, and blocked in 2% bovine
serum albumine in PBS for 20 min. Incubation with the
primary antibody rabbit-a-protein disulfide-isomerase
(PDI, Stressgen, Ann Arbor, Michigan, USA) was performed
for 2 hr. After being washed in PBS, coverslips were stained
with donkey-a-rabbit Alexa 568 (Invitrogen) for 45 min.
Coverslips were washed again with PBS and briefly with
milliQ before being mounted in Vectashield containing
DAPI (Vector Laboratories, Burlingame, CA, USA). The
localization of constructs was analyzed with a Zeiss Axio
Imager Z1 fluorescence microscope equipped with a 633
objective lens.PNGaseF Assay
COS-1 cells were transfected with DNA constructs encod-
ing either the wild-type IMPG2-SEA domain or the
DRSPKENDmutant in the pSeqTag vector. After 24 hr, cells
were lysed in lysis buffer (50 mM Tris-HCl [pH 7.5],The Americ150 mM NaCl, and 0,5% Triton X-100) and supplemented
with complete protease inhibitor cocktail (Roche Diagnos-
tics, Mannheim, Germany), and lysates were cleared by
centrifugation for 10 min at 4C and 12,500 rpm. Part of
the protein lysates were incubated overnight at 37C
with PNGaseF according to the manufacturer’s protocol
(New England Biolabs, Hitchin, UK). PNGaseF-treated
and -untreated samples were run on a NuPAGE Novex
4%–12% Bis-Tris SDS-PAGE gel (Invitrogen). Proteins
were transferred onto a nitrocellulose membrane, and the
IMPG2 SEA wild-type or DRSPKEND mutant proteins
were analyzed with the monoclonal mouse a-GFP primary
antibody (Roche Diagnostics) that also exhibits reactivity
against eCFP. As a secondary antibody, goat-a-mouse
coupled to IRDye800 (Rockland Immunochemicals,
Gilbertsville, PA, USA) was used. Signals were recorded on
a Li-Cor Odyssey 2.1 infrared scanner.Results
Homozygosity Mapping and Mutation Detection
Whole-genome SNP analysis of 381 RP and 193 LCA
patients of Israeli, Palestinian, and European origins
revealed two RP families in which the affected siblings
shared a large homozygous region at 3q12 (Table 1).
In these two families (MOL0764 andW01-299), the region
on chromosome 3 was the only large region that was
homozygous in all affected relatives. In family MOL0764,
an Israeli family of Iraqi Jewish origin, the 38 Mb critical
interval was flanked by rs1036051 and rs326333
(Figure 1A). Microsatellite analysis in the Dutch family
W01-299, including parents and nonaffected siblings,
revealed that this region segregated with the disease, andan Journal of Human Genetics 87, 199–208, August 13, 2010 201
Figure 1. Pedigrees and Segregation Analysis in Two Families
with IMPG2 Mutations
(A) Family MOL0764: selected SNP markers encompassing the
shared homozygous region in IV:2 and IV:3 as detected by the
10K Affymetrix array are shown in the right panel. The rs481809
marker is located within the IMPG2 gene.
(B) Family W01-299: microsatellite and SNP analysis shows
cosegregation of a chromosome-3q-linked haplotype with RP in
family W01-299; the flanking SNPs are indicated in italics. Muta-
tion-bearing haplotypes are marked by black bars.
Filled symbols represent affected individuals, whereas clear
symbols represent unaffected individuals. The position of the
markers (in Mb), based on the human genome browser
GRCh37/hg19, is indicated.a critical interval of 12.8 Mb, flanked by rs12330531 and
rs2290477, was detected (Figure 1B). The overlapping
interval of the two families spans 7.3 Mb, flanked by
rs12330531 and rs326333 (Figure 2A). One of the 30 anno-
tated genes in the overlapping region is the interphotore-
ceptor matrix proteoglycan 2 (IMPG2: MIM *607056)
gene, which has previously been reported to be expressed
specifically in the retina22–24 and encodes a protein
localized to the IPM.22,23 IMPG2 is speculated to be highly
important for retinal adhesion25 and therefore is an
excellent candidate gene for retinal diseases.26 Mutation
analysis of IMPG2 in the two probands of these families
revealed two different disease-causingmutations. In family
MOL0764, a homozygous nonsensemutation (c.635C>G;
p.Ser212X) was identified in exon 6 (Figure 2D; Figure S1)
in all three affected individuals. The mutation was not
identified in 47 additional RP patients of Oriental Jewish
origin (mainly from Iraq, Iran and Afghanistan), nor in202 The American Journal of Human Genetics 87, 199–208, August 198 Israeli and Palestinian RP patients from other origins.
The nonsense mutation was found heterozygously in one
out of 104 controls of Oriental Jewish ancestry. In family
W01-299, exon 9 of IMPG2 failed to amplify in the affected
individuals (Figure 2B, upper panel), suggesting the pres-
ence of a homozygous deletion. RT-PCR analysis of
IMPG2 cDNA derived from EBV-transformed lymphoblas-
toid cells revealed that exon 9 was absent from the mRNA
in the affected individuals of family W01-299 (Figure 2C).
Using several primer pairs located in introns 8 and 9 of
IMPG2, we identified a 1850 bp genomic deletion that
removes exon 9 (c.888-1554_908þ274del) (Figure 2B,
lower panel) and found that it segregated with RP
(Figure 2B). The absence of exon 9 results in the deletion
of seven amino acids (RSPKEND) from the encoded
IMPG2 protein without affecting the reading frame
(p.Arg296_Asp302 del; Figures 2C and 2D). The deletion
was not present in 270 Dutch control individuals or in
more than 700 probands who were of European origin
and had isolated or autosomal-recessive RP.
In ten additional families with retinal disease, significant
IMPG2-harboring homozygous regions, ranging from 13.6
to 80.8 Mb of genomic DNA, were identified (Table 1).
Mutation analysis revealed five additional mutations in
families from Israel, The Netherlands, Italy, and Pakistan;
most of these mutations were associated with a diagnosis
of RP (Table 1; Figure S1). In two Dutch siblings (family
W08-1378), of which only the proband was genotyped
on a SNP array, a homozygous nonsense mutation was
identified (c.2716C>T; p.Arg906X). In two unrelated
Italian RP patients from families NAP1 and NAP75, two
additional homozygous nonsense mutations were
identified (c.2890C>T; p.Arg964X and c.3262C>T;
p.Arg1088X, respectively). In a Pakistani family (RP-49)
with three affected individuals, another nonsense muta-
tion was identified (c.1680T>A; p.Tyr560X). None of these
mutations were identified in more than 100 ethnically
matched control individuals, and each of them segregated
with the disease in each of the families. The p.Arg906X
mutation that was identified in the Dutch family
W08-1378 was also present in a heterozygous state in an
isolated RP patient from The Netherlands. However, no
mutation on the second allele was detected by sequence
analysis of all exons and intron-exon boundaries in this
particular patient.
In addition, in an isolated patient who hadmaculopathy
and was of Israeli Arab Christian origin, a homozygous
nucleotide transition (c.370T>C) that is predicted to result
in a missense mutation (p.Phe124Leu) (Figure S1) affecting
a highly conserved phenylalanine residue (Figure 2E) was
identified.
Clinical Evaluation of Patients with IMPG2Mutations
Complete ophthalmic examinations were performed
in all patients with mutations in IMPG2. In general,
affected individuals with IMPG2 mutations displayed
typical symptoms and signs of RP; these included night3, 2010
Figure 2. Linkage Intervals, Mutation Analysis, and Protein Characterization of IMPG2
(A) Upper panel: part of chromosome 3 showing the linkage intervals and the corresponding flanking SNPs for arRP-families MOL0764
and W01-299. The genomic positions of these markers are indicated in Mb. IMPG2 resides within the region that is shared by the two
families. Lower panel: genomic structure of IMPG2; 19 exons are indicated as blue bars. The noncoding parts of exons 1 and 19 are indi-
cated with a smaller bar.
(B) Upper panel: PCR analysis of exon 9 of IMPG2. Exon 9 was not amplified in the three affected individuals of family W01-299.
All relatives and their position in the pedigree are indicated above the electropherogram. Lower panel: after identification of the break-
points of the genomic deletion, PCR primers were designed to amplify a product if the deletion is present. This breakpoint PCR shows
a product in all three affected individuals and in the heterozygous carriers, i.e., both parents (I:1 and I:2) and one unaffected brother (II:3).
(C) Sequence analysis of IMPG2 mRNA derived from EBV-transformed cultured lymphoblasts of individual II:1 and of an unrelated
control. RT-PCR and subsequent analysis shows that, because of the genomic deletion, exon 9 of IMPG2 is absent in the mutant
IMPG2 mRNA. At the protein level, this is predicted to result in the absence of seven amino acids, i.e., RSPKEND.
(D) Graphical representation of the IMPG2 protein. Shown are the signal peptide, two SEA domains and two EGF-like domains in the
large extracellular N-terminal part of the protein, and a transmembrane-spanning region. The positions of asparagine and threonine
residues that are predicted to undergo N- or O-linked glycosylation, respectively, as well as the serine residues that might serve as
core residues for the attachment of glycosaminoglycan side chains, are indicated with symbols described in the figure. The positions
of the mutations identified in this study are indicated with arrows.
(E) Evolutionary conservation of the mutated phenylalanine residue and surrounding amino acids. Shown are partial protein sequences
of human, mouse, bovine, and chicken IMPG2 and IMPG1 proteins. Amino acids that are identical in all proteins are presented in white
on a black background, whereas partially conserved residues are shown in black on a gray background.blindness, loss of the visual field, optic-disc pallor,
attenuated vessels, and bone-spicule-like pigmentations.
However, some inter- and intrafamilial variability was
noted. The three sisters of family MOL0764 were diag-The Americnosed with RP and myopia at childhood and in their sixth
decade had advanced RP with very low visual acuity
(ranging from only the ability to count fingers to only
the ability to perceive light), atrophic macular changes,an Journal of Human Genetics 87, 199–208, August 13, 2010 203
and severely constricted visual fields (Table 2, Figures 3A
and 3B). In all three patients, full-field ERG responses
were extinguished. The three affected siblings of family
W01-299 were diagnosed with RP before the age of 15.
Visual acuity varied from 20/125 to 20/32 at the time of
presentation. The ERG responses in two of the siblings
showed a rod-cone pattern and deteriorated over time.
Posterior subcapsular cataracts led to cataract extraction
in all three patients around the age of 30. All three featured
a bull’s-eye maculopathy (Figure 3C). The two affected
siblings of family W08-1378 presented with early-onset
night blindness and diminished color vision and were
diagnosed with rod-cone dystrophy in their teens. At age
30, they both displayed moderate myopia, a waxy pallor
of the optic disc, narrow vessels, some bone spicules in
the periphery (Figures 3D–3G), and an undetectable ERG
response (Table 2). The proband had a relatively intact
macula with a visual acuity of 20/80 in both eyes and
only loss of sensitivity in the central visual field. His
younger brother, however, had patches of RPE atrophy in
the macula (Figures 3F and 3G) and a visual acuity of
20/80 (right eye) and only enough visual acuity to count
fingers (left eye), and visual-field testing showed a central
scotoma in both eyes. The patient of family NAP1 was
diagnosed with RP at the age of 30. Her clinical presenta-
tion in the late sixth decade of life showed advanced RP
with atrophic macular changes, very low visual acuity,
exotropia in the right eye, nystagmus, and posterior
subcapsular cataracts, and her ERG was extinguished
(Table 2). The patient of family NAP75 was diagnosed
with RP during childhood, and in the sixth decade of life
she had advanced RP with low visual acuity and atrophic
macular changes. Her full-field ERG was extinguished,
and the retinal degeneration was accompanied by poste-
rior subcapsular cataracts that led to cataract extraction
(Figure 3H, Table 2). In contrast to the patients with RP
due to null mutations, patient MOL0732, with a homozy-
gous missense mutation, was diagnosed with mild macul-
opathy at the age of 63. Her full-field ERG was within
normal limits, her color vision was normal, and her best
corrected visual acuity was 20/40 and 20/50 (Table 2).
Fundus examination revealed a mild maculopathy (Figures
S2A and S2B), and OCT analysis revealed elevation of the
photoreceptor layer in the foveal region (Figures S2C and
S2D). Visual-field testing revealed a relative central
scotoma in the right eye, whereas in the left eye, the visual
field was within normal limits.
Functional Analysis of the DRSPKEND Mutation
To assess the consequences of the DRSPKENDmutation on
the function of IMPG2, we analyzed the effect of the muta-
tion on its glycosylation and protein trafficking. Using bio-
informatic prediction programs for N- and mucin-type-O-
linked glycosylation, we predicted that five asparagine resi-
dues (Asn154, Asn301, Asn320, Asn370, and Asn942) as
well as four threonine residues (Thr190, Thr192, Thr544,
and Thr556) would undergo N- and O-linked glycosyla-204 The American Journal of Human Genetics 87, 199–208, August 1tion, respectively (Figure 2D). In addition, two conserved
serine residues have been found to serve as the core resi-
dues to which glycosaminoglycan side chains are attached
(Figure 2D).23 The seven amino acids deleted in the
DRSPKEND mutant protein are located in the first SEA
domain, which contains two predicted sites for the
N-linked glycosylation of IMPG2. To determine whether
the DRSPKEND mutant protein shows an impaired glyco-
sylation, we subcloned the cDNA encoding the first SEA
domain of IMPG2 into the pSeqTag vector both for the
wild-type sequence and the DRSPKEND mutant. COS-1
cells were transiently transfected with the wild-type or
the mutant construct, and 24 hr after transfection, cells
were lysed and proteins were extracted. Part of the protein
lysates were treated with PNGaseF, which removes
N-linked carbohydrates, and subsequently subjected to
SDS-PAGE. Immunoblot analysis showed no difference
in migration of the proteins between PNGaseF-treated
and -untreated lysates for either the wild-type or the
DRSPKEND mutant IMPG2 protein (data not shown).
These results indicate that the two asparagine residues
that are predicted to undergo N-linked glycosylation are
not glycosylated in COS-1 cells.
To determine whether the fusion proteins are properly
targeted into the secretory pathway, we seeded COS-1 cells
onto glass coverslips and transfected them with the same
constructs. Fluorescence microscopy analysis showed
that the fusion protein containing the wild-type IMPG2
SEA domain is present in vesicle-like structures in the
endoplasmic reticulum (ER) and throughout the cyto-
plasm and is able to reach the cellular membrane (Figures
4A–4C). Intriguingly, the DRSPKEND mutant SEA domain
appears to be trapped in the ER, which is observed as an
accumulation of fluorescent protein adjacent to the
nucleus, partially co-localizing with the ER-marker protein
disulfide-isomerase (PDI) (Figure 4D–4F).Discussion
In this study, seven different mutations in IMPG2 were
identified in seven families of various ethnic origins.
IMPG2 encodes the retinal interphotoreceptor matrix
proteoglycan IMPG2 (also known as IPM200 or
SPACRCAN), that consistsof1,241aminoacidswithacalcu-
lated molecular weight of 138.5 kDa.22,24 The IMPG2
protein is highly similar to IMPG1 (also known as SPACR)
and is predicted to contain a signal peptide, two SEA
domains, and two EGF-like domains in the large extracel-
lular N-terminal part of the protein, a putative transmem-
branedomain, and a cytoplasmic tail.22,23 IMPG2 is synthe-
sizedby thephotoreceptor cells and is secreted into the IPM.
Both IMPG1 and IMPG2 have been shown to bind to
hyaluronan, a glycosaminoglycanmolecule that is essential
for theorganizationof the IPM, and the sites forhyaluronan
binding have been mapped in the mouse Impg2
protein.25,273, 2010
Table 2. Clinical Characteristics of Patients with Mutations in IMPG2
Patient
Age
(yr) Gender
Visual
Acuitya
Refract.
errora,b Lens Ophthalmoscopy
Goldmann
Perimetry ERG
MOL0764
IV:1
66 F LP
LP
12.00
11.75
PSC and
nuclear
cataract
Posterior staphyloma, optic
disc pallor, attenuated vessels,
atrophic maculopathy, RPE
atrophy with bone spicules
in periphery
<5 NR
MOL0764
IV:2
60 F HM
HM
8.25
5.50
PSC
cataract
Myopic changes, optic disc
pallor, attenuated vessels,
RPE atrophy in posterior
pole and periphery with
bone spicules
5 NR
MOL0764
IV:3
52 F CF
CF
3.00
3.25
Mild PSC Optic disc pallor, attenuated
vessels, RPE atrophy in posterior
pole and periphery with
bone-spicules
Peripheral island NR
W01-299
II:1
59 F LP
LP
4.00c
4.00c
IOL Optic disc pallor, attenuated
vessels, bull’s-eye maculopathy,
RPE atrophy with bone-spicules
in periphery
n.p. NRd
W01-299
II:5
45 M 20/200
LP
0.25
0.25
IOL Optic disc pallor, attenuated
vessels with sheathing, subtle
bull’s eye maculopathywith ERM,
RPE atrophy with bone-spicules
in periphery
10 RE,
LE n.p.
Significantly reduced,
rod-cone patterne
W01-299
II:6
44 M 20/200
20/200
0.00
þ1.25
IOL Optic disc pallor, attenuated
vessels, bull’s-eye maculopathy,
RPE atrophy with bone spicules
in periphery
10 Significantly reduced,
rod-cone patternf
W08-1378
proband
39 M 20/80
20/80
5.00
6.75
Mild
cortical
cataract
Optic disc pallor, attenuated
vessels, relatively intact macula
with bone spicules in periphery
Diminished sensitivity
BE, LE small absolute
scotoma in midperiphery
NR
W08-1378
affected
brother
36 M 20/80
CF
3.50
4.00
Mild
cortical
cataract
Optic disc pallor, attenuated
vessels, patchy RPE atrophy
in macula with bone spicules
in periphery
BE central and
paracentral scotoma
NR
NAP1
proband
68 F HM
HM
n.pg PSC
cataract
Optic disc pallor, attenuated
vessels, atrophic maculopathy,
RPE atrophy with bone spicules
in periphery
n.p. NR
NAP75
proband
64 F 20/600
20/2400
n.ph pseudo-
phakia
Optic disc pallor, attenuated
vessels, atrophic maculopathy
with ERM, RPE atrophy with
bone spicules in periphery
n.p. NR
RP-49
proband
20 M n.p. n.p n.p. Optic disc pallor, attenuated
vessels, RPE atrophy with
bone-spicules in periphery
n.p. Significantly reduced,
rod-cone pattern
MOL0732
proband
63 F 20/40
20/50
þ2.25
þ2.25
Mild
nuclear
sclerosis
Mild maculopathy
RE > LE
RE central scotoma
LE within normal
limits
Within normal limits
Abbreviations are as follows: BE, both eyes; LE, left eye; RE, right eye; LP, light perception; HM, hand motion; CF, counting fingers; PSC, posterior subcapsular
cataract; IOL, intra ocular lens; n.p., not performed; NR, nonrecordable; RPE, retinal pigment epithelium; and ERM, epiretinal membrane.
a The upper line represents the right eye, and the lower line represents the left eye.
b Spherical equivalent in Dioptres.
c Refractive error pre-cataract extraction
d ERGs performed at 8 and 27 years of age
e ERGS performed at 14 and 30 years of age
f ERGs performed at 12 and 23 years of age
g Refractive error pre-cataract extraction not available
h Refractive error not available because of advanced cataractFive of the seven mutations found in this study intro-
duce premature stop codons that will either result in
nonsense-mediated degradation of the IMPG2 mRNA orThe Americproduce truncated IMPG2 proteins that would all lack
the transmembrane domain and the cytoplasmic tail
(Figure 2D). As such, these mutations can be consideredan Journal of Human Genetics 87, 199–208, August 13, 2010 205
Figure 3. Fundus Photographs of RP Patients with IMPG2
Mutations
(A and B) A montage of color fundus photos of MOL0764 IV:2 at
age 60 shows advanced RP along with myopic changes.
(C) Fundus photographs of the right eye of patient W01-299 II:6,
aged 44 years, show optic-disc pallor, attenuated vessels, bull’s eye
maculopathy, and mid-peripheral RPE atrophy with some intra-
retinal pigmentations.
(D–G) Family W08-1378: (D and E) Montage of color fundus
photos of the proband and (F and G) fundus photographs of the
affected brother. Both show optic disc pallor, attenuated vessels,
and patchy depigmentation of the RPE in the midperiphery with
some bone spicules. Only the brother presented with sharply
delineated atrophy of the RPE in the macula of both eyes.
(H) A fundus photograph of the left eye of proband NAP75, aged
64 years, shows optic-disc pallor, attenuated vessels, atrophic mac-
ulopathy, and mid-peripheral RPE atrophy with some intra-retinal
pigmentations.
(I and J) A fundus photograph of both eyes of the proband of
family RP-49 shows optic-disc pallor, attenuated vessels, and
bone-spiculed pigmentations.true loss-of-function alleles. The two other mutations
(c.888-1554_908þ274del and c.370T>C), however, do
not truncate the IMPG2 protein but only slightly alter
the amino acid composition. The genomic deletion
detected in the Dutch family (W01-299) results in the
absence of exon 9 in the mutant IMPG2 mRNA but does
not disrupt the reading frame. At the protein level, seven
amino acids (RSPKEND) are absent. These amino acids
are located in the first SEA domain (named because of
homology to domains present in sperm protein, enteroki-
nase, and agrin), which contains two predicted sites for the
N-linked glycosylation of IMPG2; one of these sites is206 The American Journal of Human Genetics 87, 199–208, August 1located within the deleted peptide sequence (Figure 2D).
In addition, the 7 amino acid peptide sequence precedes
a serine-glycine motif, of which the serine residue might
be the core residue to which glycosaminoglycan side
chains are attached.28 The SEA domains are frequently
found in heavily glycosylated environments, and their
proposed function is to regulate or assist binding to neigh-
boring carbohydrate moieties. The first predicted SEA
domain of IMPG2 resides within a predicted mucin-like
sequence that is thought to play a role in the proper glyco-
sylation of the protein. Subcellular localization assays
showed that the DRSPKEND mutant protein is trapped in
the ER, whereas the wild-type protein is targeted to the
plasma membrane, suggesting that the absence of the
seven amino acids impairs proper targeting of the IMPG2
protein to the cell membrane and as such might affect
normal IMPG2 function in the IPM.
The missense mutation that was detected in the patient
with maculopathy substitutes a leucine residue for
a phenylalanine residue (p.Phe124Leu). This phenylala-
nine residue is highly conserved, not only in orthologous
IMPG2 proteins but even in the sequence of the homolo-
gous IMPG1 proteins (Figure 2E). Phenylalanine residues
have a large and bulky side chain that contains an aromatic
ring, whereas leucine residues are somewhat smaller. The
phenylalanine at position 124 is not located in one of
the domains that are predicted to be glycosylated or to
be involved in hyaluronan binding. However, given the
high conservation of this residue in IMPG1 and IMPG2
proteins, in addition to the absence of this allele in ethni-
cally matched control individuals, our data indicate that
this amino acid substitution might be causative for macul-
opathy in the patient from family MOL0732. As such, this
clinical case suggests that missense mutations in IMPG2
might cause a less severe phenotype than nonsense muta-
tions. The association between IMPG2missense mutations
and maculopathy, as well as the mechanism underlying
this possible genotype-phenotype correlation, requires
further examination.
In a previous report, the IMPG2 gene has been analyzed
for mutations in 224 patients with various retinal diseases
(mainly age-related macular degeneration, RP, and LCA),
but no mutations were identified.26 Analysis of the homol-
ogous IMPG1 gene did not reveal mutations in patients
with autosomal-dominant Stargardt-like macular
dystrophy, progressive bifocal chorioretinal atrophy, and
North Carolina macular dystrophy.29 A study involving
a Dutch family with autosomal-dominant benign concen-
tric annular macular dystrophy that linked to the IMPG1
locus identified a missense variant (p.Leu579Pro) that
affects a residue that is highly conserved among IMPG1
and IMPG2 orthologs of various species and is suggested
to be the causal mutation.30
Although the exact role of IMPG2 within the IPM is
unknown, absence or impaired function of this protein
probably affects the structure or function of the IPM and
consequently might affect the visual processes in the3, 2010
Figure 4. Subcellular Localization of Wild-Type and DRSPKEND Mutant SEA-Domain Fusion Proteins
(A–C) Images of COS-1 cells transiently transfected with a wild-type IMPG2-SEA domain fused to a signal peptide and eCFP. The wild-
type fusion protein ([A], in green) localizes to vesicle-like structures in the ER ([B], PDI staining, red) and cytoplasm (open arrows) and is
present at the cellular membrane (filled arrows). Nuclei are stained with DAPI (blue). (C) Overlay of (A) and (B).
(D–F) Images of COS-1 cells transiently transfected with DRSPKENDmutant IMPG2-SEA domain fused to a signal peptide and eCFP. The
mutant fusion protein ([D], in green) accumulates in an ER-like region adjacent to the cell nucleus (arrow heads) and does not reach the
plasma membrane. (E) PDI staining of the ER, red. Nuclei are stained with DAPI, blue. (F) Overlay of (D) and (E).photoreceptor cells. The identification of IMPG2 muta-
tions in arRP in this report underscores the importance
of the retinal ECM for maintaining retinal structure and
function.Supplemental Data
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found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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